Floatz logo

gw786034

Clear-cell Metastatic Renal Cell Carcinoma

Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoPhase 4 / ApprovedDormant
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

116 Active assets in the Clear-cell Metastatic Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Girentuximab
Massachusetts General Hospital
Phase 3BB
gw786034
Academic and Community Cancer Research United
Phase 4BB
CLOSTRIDIUM BUTYRICUM MIYAIRI 588
City of Hope Medical Center
Phase 3BB
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Regeneron Pharmaceuticals
Phase 2BB
Nivolumab
Fred Hutchinson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

gw786034 is also rated in:

renal cell carcinomaDormant
BBB
Indicative ·
79 / 100
View asset →
ovarian neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →